PMID- 38396877
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240227
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 25
IP  - 4
DP  - 2024 Feb 12
TI  - Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
LID - 10.3390/ijms25042203 [doi]
LID - 2203
AB  - Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for 
      relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas 
      (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it 
      as a systemic treatment, especially for advanced disease stages due to its 
      comparatively lower toxicity. Clinical trials and real-world evidence have 
      underscored its efficacy in advanced CTCLs, including mycosis fungoides and 
      Sezary syndrome; PTCLs; and adult T-cell leukemia/lymphoma (ATLL), showcasing 
      positive outcomes. Notably, the drug has demonstrated significant response rates, 
      disease stability, and extended periods of progression-free survival, suggesting 
      its applicability in cases with multiple treatment lines. Its safety profile is 
      generally manageable, with adverse events (AEs) primarily related to the skin, 
      infusion-related reactions, drug eruptions, autoimmune diseases, and skin 
      disorders. The latter seem to appear as CCR4 can promote the skin-specific homing 
      of lymphocytes, and MOG is directed against this receptor. While combination with 
      immunostimulatory agents like interferon alpha and interleukin 12 has shown 
      promising results, caution is urged when combining with PD1 inhibitors due to the 
      heightened risk of immune-mediated AEs. The introduction of MOG as a systemic 
      treatment implies a significant advancement in managing these diseases, supported 
      by its favorable safety profile and complementary mechanisms.
FAU - Fernandez-Guarino, Montserrat
AU  - Fernandez-Guarino M
AD  - Dermatology Department, Hospital Universitario Ramon y Cajal, Instituto de 
      Investigacion Sanitaria Ramon y Cajal (Irycis), 28034 Madrid, Spain.
FAU - Ortiz, Pablo
AU  - Ortiz P
AD  - Dermatology Department, Hospital 12 de Octubre, 28041 Madrid, Spain.
FAU - Gallardo, Fernando
AU  - Gallardo F
AD  - Dermatology Department, Hospital del Mar, 08003 Barcelona, Spain.
FAU - Llamas-Velasco, Mar
AU  - Llamas-Velasco M
AUID- ORCID: 0000-0002-1187-1341
AD  - Dermatology Department, Hospital Universitario de la Princesa, Fundacion de 
      Investigacion Biomedica de la Princesa, 28006 Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240212
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - YI437801BE (mogamulizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Lymphoma, T-Cell, Cutaneous/drug therapy
MH  - *Mycosis Fungoides/pathology
MH  - *Sezary Syndrome/pathology
MH  - *Leukemia-Lymphoma, Adult T-Cell/drug therapy/pathology
MH  - *Skin Neoplasms/pathology
MH  - *Antibodies, Monoclonal, Humanized
PMC - PMC10889597
OTO - NOTNLM
OT  - cutaneous T-cell lymphoma
OT  - effectiveness
OT  - mogamulizumab
OT  - peripheral T-cell lymphoma
COIS- Mar Llamas-Velasco is an advisory board member, consultant, research support, 
      participant in clinical trials, and speaker for the following pharmaceutical 
      companies: Abbvie, Almirall, Amgen, Boehringer, Celgene, Janssen, Leo, Lilly, 
      Kyowa Kirin, Novartis, and UCB. Fernando Gallardo is an advisory board member, 
      consultant, research support, participant in clinical trials, and speaker for the 
      following pharmaceutical companies: Abbvie, Almirall, Amgen, Boehringer, Celgene, 
      Janssen, Leo, Lilly, Kyowa Kirin, Novartis, and UCB. Pablo L Ortiz Romero has 
      served as an advisor or speaker for Kyowa Kirin, Takeda, 4SC, Mallincrodt, 
      Recordati Rare Diseases, Actelion, MIRAGEN, Biopropharma, and Innate Pharma.
EDAT- 2024/02/24 11:44
MHDA- 2024/02/26 06:42
PMCR- 2024/02/12
CRDT- 2024/02/24 01:03
PHST- 2023/12/02 00:00 [received]
PHST- 2024/02/05 00:00 [revised]
PHST- 2024/02/05 00:00 [accepted]
PHST- 2024/02/26 06:42 [medline]
PHST- 2024/02/24 11:44 [pubmed]
PHST- 2024/02/24 01:03 [entrez]
PHST- 2024/02/12 00:00 [pmc-release]
AID - ijms25042203 [pii]
AID - ijms-25-02203 [pii]
AID - 10.3390/ijms25042203 [doi]
PST - epublish
SO  - Int J Mol Sci. 2024 Feb 12;25(4):2203. doi: 10.3390/ijms25042203.